New hope for brain cancer: targeted drug combo shows promise

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a full understanding of this study and voluntarily sign the informed consent form. * Untreated patients with primary central nervous system lymphoma (PCNSL) confirmed by pathology (immunotyping) according to the 2016 WHO classification of lymphoid neoplasms. * Diffuse large B-cell lymphoma (DLBCL) originating from the central nervous system (CNS) without involvement of other organs, confirmed by PET-CT or contrast-enhanced CT. * Expected survival greater than 3 months. * Laboratory test results meeting all of the following: * Creatinine clearance rate ≥ 50 mL/min (calculated by the Cockcroft-Gault formula). * International normalized ratio (INR) ≤ 1.5 × ULN or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN. Patients on warfarin may have INR 2-3. * Left ventricular ejection fraction (LVEF) ≥ 50%. * Glomerular filtration rate (GFR) ≥ 60 mL/min. * Male or female patients of childbearing potential must agree to use effective contraception (e.g., double-barrier methods, condoms, oral or injectable contraceptives, intrauterine device) during the study and for 30 days after the last dose. * Postmenopausal women (\> 45 years old and amenorrheic \> 1 year) or surgically sterilized women are exempt from this requirement. Exclusion Criteria: * Contraindication to any drug included in the treatment regimen. * History of clinically significant liver disease, including viral or other hepatitis or cirrhosis. * Hepatitis B: Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with HBV-DNA above ULN. * Active hepatitis C: Positive HCV antibody with detectable HCV-RNA. * Human Immunodeficiency Virus (HIV) infection. * Congestive heart failure (New York Heart Association Class \> II) or history within 6 months of acute myocardial infarction, unstable angina, stroke, or transient ischemic attack. * Hereditary long QT syndrome or QTc \> 480 ms (QTc calculated using Fridericia's formula, QTcF = QT / RR\^0.33). * Other malignancies within 5 years, except: completely cured cervical carcinoma in situ, basal cell carcinoma of the skin, breast carcinoma in situ, or another primary cancer that has been cured and not recurred within 5 years. * Pregnant or lactating women, or women planning pregnancy during the study period. * History of significant neurological or psychiatric disorders, including substance or psychotropic-drug abuse. * Clinically significant active infection. * Inability to take or swallow oral medication, or conditions affecting drug absorption (e.g., chronic diarrhea, intestinal obstruction).